跳至主要内容
临床试验/NCT07307170
NCT07307170招募中不适用

The Analgesic Efficacy and Safety of Oral Medications (Mirogabalin) in Patients With Herpes Zoster

Beijing Tiantan Hospital1 个研究点 分布在 1 个国家目标入组 750 人开始时间: 2025年12月15日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
招募中
发起方
入组人数
750
试验地点
1
主要终点
the average numeric rating scale score over the past 24 hours, rated each morning upon awakening and average over 7 days at week 4

研究概览

简要总结

Herpes zoster (HZ) is characterized by a painful dermatomal rash and significantly affects quality of life, with acute pain increasing the risk of postherpetic neuralgia. Although early antiviral therapy limits viral replication, its analgesic effect is insufficient, and many patients experience inadequate relief despite stepwise use of non-opioids and opioids. Gabapentinoids such as gabapentin and pregabalin are recommended adjuncts, but their efficacy in acute HZ is inconsistent and often accompanied by adverse effects that limit tolerability. Mirogabalin, a newer gabapentinoid approved for peripheral neuropathic pain, has higher affinity and slower dissociation from the α2δ-1 subunit, suggesting stronger analgesia with fewer central side effects. However, its role in managing acute HZ pain remains unknown. We therefore hypothesize that adding mirogabalin to conventional therapy will provide superior pain relief compared with standard treatment alone, and propose a prospective, randomized, controlled, open-label, blinded-endpoint trial to evaluate this.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 1. Ages more than 18 years;
  • 2. Patients with onset of HZ rash less than 90 days;
  • 3. Experiencing moderate to severe HZ pain with an average pain score of at least 4 on a Numeric Rating Scale (NRS, 0 = no pain, 10 = worst possible pain);
  • 4. Aspartate aminotransferase and alanine aminotransferase levels less than twice the upper limit of normal;
  • 5. Estimated glomerular filtration rate of 30 mL/min per 1.73 m2 or higher;
  • 6. Willing to sign the informed consent form and possessing sufficient cognitive and language abilities to comply with all the study requirements.

排除标准

  • 1. History of taking gabapentin or pregabalin;
  • 2. Patients with evidence of cutaneous or visceral dissemination of HZ infection (cutaneous dissemination is defined as more than 20 discrete lesions outside adjacent dermatomes) or ocular involvement of HZ;
  • 3. History of intolerance or hypersensitivity to any active components or excipient of the mirogabalin;
  • 4. History of systemic immune diseases, organ transplantation, or cancers;
  • 5. Pregnancy or breastfeeding;
  • 6. Suffering from acute or chronic pain disorders other than HZ.

研究组 & 干预措施

Mirogabalin group

Experimental

干预措施: Mirogabalin combined conventional therapy (Drug)

Control group

Active Comparator

干预措施: Conventional therapy (Drug)

结局指标

主要结局

the average numeric rating scale score over the past 24 hours, rated each morning upon awakening and average over 7 days at week 4

时间窗: At week 4 after experimental drug medication

The numeric rating scale (NRS) score is a way to quantify the degree of subjective feelings such as pain using numbers. Generally, 0 represents no pain, and 10 represents the most severe pain. A higher score indicates more severe pain.

次要结局

  • The worst numeric rating scale score(at weeks 1, 2, 4, 8, and 12 after experimental drug medication)
  • Proportion of Patients Achieving Pain Reduction(at weeks 1, 2, 4, 8, and 12 after experimental drug medication)
  • Proportion of patients developing postherpetic neuralgia(at week 12 after experimental drug medication)
  • The type of analgesics and average weekly consumption per analgesics(at weeks 4, 8, and 12 after experimental drug medication)
  • The 12-item Short-Form Health Survey (SF-12) score(at weeks 4, 8, and 12 after experimental drug medication)
  • The Medical Outcomes Study Sleep Scale (MOS)(at weeks 4, 8, and 12 after experimental drug medication)
  • Adverse events(Through study completion, an average of 12 weeks)

研究者

发起方
Beijing Tiantan Hospital
申办方类型
Other
责任方
Principal Investigator
主要研究者

Fang Luo

Director, Department of Pain Management, Principal Investigator, Clinical Professor

Beijing Tiantan Hospital

研究点 (1)

Loading locations...

相似试验

The Analgesic Efficacy and Safety of Mirogabalin in... | 临床试验